FDA establishment 3011785119, India. Every inspection FDA has posted for the site, with its outcome and cited regulations, and the shipments FDA refused at the border.
FDA has posted no inspections for this site.
| Product | Charges | Latest |
|---|---|---|
| FEXOFENADINE HCL (ANTI-ASTHMATIC)Drugs · 61ECY06 | Oct 23, 2026 | |
| GLYBURIDE (ANTI-DIABETIC)Drugs · 61PCA11 | Sep 14, 2026 | |
| ANTI-INFLAMMATORY N.E.C.Drugs · 62GDY99 | Aug 25, 2026 | |
| HOMEOPATHIC N.E.C.Drugs · 66XCA99 | Aug 7, 20262 lines | |
| RAMIPRIL (ANTI-HYPERTENSIVE - PART II)Drugs · 62OCA05 | Jul 10, 2026 | |
| FEXOFENADINE HCL (ANTI-ASTHMATIC)Drugs · 61EDA06 | Sep 24, 2025 | |
| FEXOFENADINE HCL (ANTI-ASTHMATIC)Drugs · 61EDY06 | Jun 30, 2025 |
An FEI (FDA Establishment Identifier) names one physical site. Inspections, outcomes and citations come from FDA's Data Dashboard; FDA posts citations only for some inspections. A contract site can make products for many companies, so the company shown is the one FDA lists as the site's firm. FDA Data Dashboard and warning letters
India. Every inspection FDA has posted for the site, with its outcome and cited regulations, and the shipments FDA refused at the border.